Soligenix (STU:DOA) Interest Expense : €-0.06 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Soligenix Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Soligenix's interest expense for the three months ended in Mar. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.06 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Soligenix's Operating Income for the three months ended in Mar. 2024 was € -1.83 Mil. Soligenix's Interest Expense for the three months ended in Mar. 2024 was € 0.00 Mil. GuruFocus does not calculate Soligenix's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Soligenix Interest Expense Historical Data

The historical data trend for Soligenix's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Interest Expense Chart

Soligenix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.80

-0.78

-0.05

Soligenix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.10	-0.06	-	-	-

Soligenix Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.06 Mil.

Soligenix (STU:DOA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Soligenix's Interest Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-1.83 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €0.07 Mil.

Soligenix's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Soligenix's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Soligenix (STU:DOA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SNGX:USA

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines